CN Patent

CN112999229A — 一种包含布地奈德的口服药物组合物

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-06-22 · 5y expired

What this patent protects

本公开涉及一种包含布地奈德的口服药物组合物。具体的，所述组合物包含：a)持续释放组分，所述持续释放组分包括含药核芯、隔离层和含碱的乙基纤维素，其中所述含药核芯包含布地奈德和稳定剂，所述隔离层不含酸，b)延时释放组分，所述延时释放组分保护组合物口服后基本上在肠道中释放。本公开的药物组合物在制剂稳定性方面展现了优异的特性。

USPTO Abstract

本公开涉及一种包含布地奈德的口服药物组合物。具体的，所述组合物包含：a)持续释放组分，所述持续释放组分包括含药核芯、隔离层和含碱的乙基纤维素，其中所述含药核芯包含布地奈德和稳定剂，所述隔离层不含酸，b)延时释放组分，所述延时释放组分保护组合物口服后基本上在肠道中释放。本公开的药物组合物在制剂稳定性方面展现了优异的特性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112999229A
Jurisdiction
CN
Classification
—
Expires
2021-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.